A Novel Nanodrug for the Sensitization of Photothermal Chemotherapy for Breast Cancer

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2024 Jul 8

PMID 38974230

Authors

Ji Chuan Kong

Feng Zhou

Liting Shi

Yihui Wei

Chunhong Wu

Affiliations

Soon will be listed here.

Abstract

Owing to the complexity of tumor treatment, clinical tumor treatment has evolved from a single treatment mode to multiple combined treatment modes. Reducing the tolerance of tumors to heat and the toxicity of chemotherapy drugs to the body, as well as increasing the sensitivity of tumors to photothermal therapy and chemotherapy drugs, are key issues that urgently need to be addressed in the current cancer treatment. In this work, polylactic acid-based drug nanoparticles (PLA@DOX/GA/ICG) were synthesized with good photothermal conversion ability by encapsulating the water-soluble anticancer drug doxorubicin (DOX), photothermal conversion agent indocyanine green (ICG) and liposoluble drug gambogic acid (GA) using a double emulsion method. The preparation process of PLA@DOX/GA/ICG was examined. Gambogic acid entrapped in PLA@DOX/GA/ICG nanoparticles could act as an HSP90 protein inhibitor to achieve bidirectional sensitization to chemotherapy and photothermal therapy under 808 nm laser irradiation for the first time, effectively ablating breast cancer cells . This nanodrug was expected to be used for the efficient treatment of tumors.

References

Zhao H, Yu J, Zhang R, Chen P, Jiang H, Yu W . Doxorubicin prodrug-based nanomedicines for the treatment of cancer. Eur J Med Chem. 2023; 258:115612. DOI: 10.1016/j.ejmech.2023.115612. View

Soerjomataram I, Bray F . Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol. 2021; 18(10):663-672. DOI: 10.1038/s41571-021-00514-z. View

Pratt W, Morishima Y, Gestwicki J, Lieberman A, Osawa Y . A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases. Exp Biol Med (Maywood). 2014; 239(11):1405-13. PMC: 4318483. DOI: 10.1177/1535370214539444. View

Tian B, Wang C, Du Y, Dong S, Feng L, Liu B . Near Infrared-Triggered Theranostic Nanoplatform with Controlled Release of HSP90 Inhibitor for Synergistic Mild Photothermal and Enhanced Nanocatalytic Therapy with Hypoxia Relief. Small. 2022; 18(28):e2200786. DOI: 10.1002/smll.202200786. View

Zhi D, Yang T, OHagan J, Zhang S, Donnelly R . Photothermal therapy. J Control Release. 2020; 325:52-71. DOI: 10.1016/j.jconrel.2020.06.032. View

Zuehlke A, Johnson J . Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 2009; 93(3):211-7. PMC: 2810645. DOI: 10.1002/bip.21292. View

Sheng D, Liu T, Deng L, Zhang L, Li X, Xu J . Perfluorooctyl bromide & indocyanine green co-loaded nanoliposomes for enhanced multimodal imaging-guided phototherapy. Biomaterials. 2018; 165:1-13. DOI: 10.1016/j.biomaterials.2018.02.041. View

Hisada Y, Mackman N . Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017; 130(13):1499-1506. PMC: 5620413. DOI: 10.1182/blood-2017-03-743211. View

Xu M, Han X, Xiong H, Gao Y, Xu B, Zhu G . Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. Molecules. 2023; 28(13). PMC: 10343932. DOI: 10.3390/molecules28135145. View

10.

Weiss F, Lauffenburger D, Friedl P . Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat Rev Cancer. 2022; 22(3):157-173. PMC: 10399972. DOI: 10.1038/s41568-021-00427-0. View

11.

Zhang Y, Wang X . Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020; 13(1):165. PMC: 7716495. DOI: 10.1186/s13045-020-00990-3. View

12.

Zhang Z, Wang J, Chen C . Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging. Adv Mater. 2013; 25(28):3869-80. DOI: 10.1002/adma.201301890. View

13.

Jung Y, Park J . Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020; 52(2):183-191. PMC: 7062731. DOI: 10.1038/s12276-020-0380-6. View

14.

Acquaviva J, Smith D, Jimenez J, Zhang C, Sequeira M, He S . Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther. 2014; 13(2):353-63. DOI: 10.1158/1535-7163.MCT-13-0481. View

15.

Nam J, Son S, Ochyl L, Kuai R, Schwendeman A, Moon J . Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018; 9(1):1074. PMC: 5852008. DOI: 10.1038/s41467-018-03473-9. View

16.

Li J, Zhang W, Ji W, Wang J, Wang N, Wu W . Near infrared photothermal conversion materials: mechanism, preparation, and photothermal cancer therapy applications. J Mater Chem B. 2021; 9(38):7909-7926. DOI: 10.1039/d1tb01310f. View

17.

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

18.

Fahmy S, Elghanam R, Rashid G, Youness R, Sedky N . Emerging tendencies for the nano-delivery of gambogic acid: a promising approach in oncotherapy. RSC Adv. 2024; 14(7):4666-4691. PMC: 10840092. DOI: 10.1039/d3ra08042k. View

19.

Powers M, Workman P . Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007; 581(19):3758-69. DOI: 10.1016/j.febslet.2007.05.040. View

20.

Li P, Liu C, Zhao Y, Cao D, Chen B, Guo X . Multifunctional Covalent Organic Framework-Based Microneedle Patch for Melanoma Treatment. Biomacromolecules. 2023; 24(8):3846-3857. DOI: 10.1021/acs.biomac.3c00488. View